SCHEMBL2883080

SCHEMBL2883080

CC(C)(C)OC(=O)n1nc(CBr)c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
DTYMK P23919 1/20 0.40
ELANE P08246 11/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GPR119 Q8TDV5 2/20 0.35
BRD4 O60885 1/20 0.35
FAAH O00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29587624 1.00 POLB (0.41) POLBDTYMKELANEDDB1CRBN
SCHEMBL3104218 0.84 ELANE (0.41) POLBDTYMKELANEDDB1CRBN
SCHEMBL25703825 0.83 POLB (0.41) POLBDTYMKELANEDDB1CRBN
SCHEMBL4563149 0.82 FAAH (0.36) POLBELANEGPR119FAAH
SCHEMBL15546294 0.82 DTYMK (0.37) POLBDTYMKELANEDDB1CRBN
SCHEMBL29773369 0.82 L3MBTL1 (0.42) POLBDTYMKELANEDDB1CRBN
SCHEMBL2176354 0.82 L3MBTL1 (0.42) POLBDTYMKELANEDDB1CRBN
SCHEMBL3606964 0.81 DTYMK (0.42) POLBDTYMKELANEDDB1CRBN
SCHEMBL3347471 0.81 CHRM2 (0.43) DTYMKELANEKDM4EFAAH
SCHEMBL29588521 0.81 CHRM2 (0.43) DTYMKELANEKDM4EFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 US disclosed
US-11352330-B2 Phenoxymethyl derivatives HOFFMANN-LA ROCHE INC. (US) 2022-06-07 US disclosed
US-20200339522-A1 PHENOXYMETHYL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 US disclosed
EP-3344619-B1 PHENOXYMETHYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-10-28 EP disclosed
US-10640472-B2 Phenoxymethyl derivatives HOFFMAN-LA ROCHE INC. (US) 2020-05-05 US disclosed
EP-2781508-B9 NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS KBP BIOSCIENCES CO LTD (CN) 2019-08-21 EP disclosed
EP-2781508-B1 NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS KBP BIOSCIENCES CO LTD (CN) 2018-12-12 EP disclosed
US-20180201588-A1 PHENOXYMETHYL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-07-19 US disclosed
EP-3344619-A1 PHENOXYMETHYL DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-07-11 EP disclosed
WO-2017037146-A1 PHENOXYMETHYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2017-03-09 WO disclosed
WO-2010046780-A2 ANTI VIRAL COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-04-29 WO disclosed
EP-2121638-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-11-25 EP disclosed
WO-2009067166-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2009-05-28 WO disclosed
US-20080293664-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-11-27 US disclosed
US-20080293664-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-11-27 US disclosed
US-20080275097-A1 Non-nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME LLC 2008-11-06 US disclosed
US-20080275097-A1 Non-nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME LLC 2008-11-06 US disclosed
WO-2008076225-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-06-26 WO disclosed
WO-2008076223-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-06-26 WO disclosed
US-5859007-A TREATMENT OF DIABETES, OBESITY GLAXO WELLCOME INC. (US) 1999-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275097-A1 Non-nucleoside reverse transcriptase inhibitors RNGTT, RRM2B, RRM2 POLB 15/4885DTYMK 26/4885ELANE 2191/4885
US-20200339522-A1 PHENOXYMETHYL DERIVATIVES CNKSR1, RB1, RCOR1 POLB 1967/4885DTYMK 3951/4885ELANE 2985/4885
US-20080293664-A1 Non-nucleoside reverse transcriptase inhibitors XDH, REV1, RTF1 POLB 169/4885DTYMK 534/4885ELANE 634/4885
US-10640472-B2 Phenoxymethyl derivatives CNKSR1, RB1, RCOR1 POLB 1967/4885DTYMK 3951/4885ELANE 2985/4885
US-20180201588-A1 PHENOXYMETHYL DERIVATIVES CNKSR1, RB1, RCOR1 POLB 1967/4885DTYMK 3951/4885ELANE 2985/4885
US-11352330-B2 Phenoxymethyl derivatives CNKSR1, RB1, RCOR1 POLB 1967/4885DTYMK 3951/4885ELANE 2985/4885
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 POLB 3557/4885DTYMK 3135/4885ELANE 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.